Franck Zal, founder of Hemarina based in Morlaix, Finistère, presented his case to the Senate's social affairs commission on Wednesday, February 18, 2026, advocating for broader access to his medical innovation, HEMHealing®. This product, derived from the hemoglobin of marine worms (arénicoles) harvested from Brittany and Vendée, possesses an oxygen-carrying capacity up to 40 times greater than human blood. HEMHealing® has already demonstrated efficacy in treating burn victims from the Crans-Montana fire, and Zal seeks to expand its therapeutic applications, particularly in facilitating organ transplants. His efforts aim to overcome regulatory hurdles and make this groundbreaking treatment more widely available.